Literature DB >> 18675323

Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

R Pattarini1, Y Rong, C Qu, J I Morgan.   

Abstract

The etiology of idiopathic Parkinson's disease is thought to involve interplay between environmental factors and predisposing genetic traits, although the identification of genetic risk factors remain elusive. The neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine (MPTP) produces parkinsonian-like symptoms and pathology in mice and humans. As sensitivity to MPTP is genetically determined in mice this provides an opportunity to identify genes and biological mechanisms that modify the response to an exogenous agent that produces a Parkinson's disease-like condition. MPTP primarily targets dopaminergic nerve terminals in the striatum and elicits changes in striatal gene expression. Therefore, we used Affymetrix and qRT-PCR technology to characterize temporal mRNA changes in striatum in response to MPTP in genetically MPTP-sensitive, C57BL/6J, and MPTP-resistant Swiss Webster and BCL2-associated X protein (Bax)-/- mice. We identified three phases of mRNA expression changes composed of largely distinct gene sets. An early response (5 h) occurred in all strains of mice and multiple brain regions. In contrast, intermediate (24 h) and late (72 h) phases were striatum specific and much reduced in Swiss Webster, indicating these genes contribute and/or are responsive to MPTP-induced pathology. However, Bax-/- mice have robust intermediate responses. We propose a model in which the acute entry of MPP+ into dopaminergic nerve terminals damages them but is insufficient per se to kill the neurons. Rather, we suggest that the compromised nerve terminals elicit longer lasting transcriptional responses in surrounding cells involving production of molecules that feedback on the terminals to cause additional damage that results in cell death. In Swiss Webster, resistance lies upstream in the cascade of events triggered by MPTP and uncouples the acute events elicited by MPTP from the damaging secondary responses. In contrast, in Bax-/- mice resistance lies downstream in the cascade and suggests enhanced tolerance to the secondary insult rather than its attenuation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18675323      PMCID: PMC2632608          DOI: 10.1016/j.neuroscience.2008.06.064

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  147 in total

1.  Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.

Authors:  Justin D Boyd; Haeman Jang; Kennie R Shepherd; Ciaran Faherty; Sally Slack; Yun Jiao; Richard J Smeyne
Journal:  Brain Res       Date:  2007-08-09       Impact factor: 3.252

Review 2.  The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Fumiaki Mori; Hitoshi Takahashi
Journal:  Neuropathology       Date:  2007-10       Impact factor: 1.906

Review 3.  ETS transcription factors and regulation of immunity.

Authors:  Sarah Gallant; Gary Gilkeson
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2006-05-02       Impact factor: 4.291

Review 4.  Mitochondria in the aetiology and pathogenesis of Parkinson's disease.

Authors:  Anthony H V Schapira
Journal:  Lancet Neurol       Date:  2008-01       Impact factor: 44.182

5.  Pael receptor is involved in dopamine metabolism in the nigrostriatal system.

Authors:  Yuzuru Imai; Haruhisa Inoue; Ayane Kataoka; Wang Hua-Qin; Masao Masuda; Toshio Ikeda; Kayoko Tsukita; Mariko Soda; Tohru Kodama; Tatsu Fuwa; Yoshiko Honda; Satoshi Kaneko; Sadayuki Matsumoto; Kazumasa Wakamatsu; Shosuke Ito; Masami Miura; Toshihiko Aosaki; Shigeyoshi Itohara; Ryosuke Takahashi
Journal:  Neurosci Res       Date:  2007-08-15       Impact factor: 3.304

6.  GSEA-P: a desktop application for Gene Set Enrichment Analysis.

Authors:  Aravind Subramanian; Heidi Kuehn; Joshua Gould; Pablo Tamayo; Jill P Mesirov
Journal:  Bioinformatics       Date:  2007-07-20       Impact factor: 6.937

7.  Role of alpha-synuclein in synaptic glutamate release.

Authors:  Irina Gureviciene; Kestutis Gurevicius; Heikki Tanila
Journal:  Neurobiol Dis       Date:  2007-06-27       Impact factor: 5.996

8.  alpha-Synuclein gene duplication is present in sporadic Parkinson disease.

Authors:  T-B Ahn; S Y Kim; J Y Kim; S-S Park; D S Lee; H J Min; Y K Kim; S E Kim; J-M Kim; H-J Kim; J Cho; B S Jeon
Journal:  Neurology       Date:  2007-07-11       Impact factor: 9.910

Review 9.  S100A10/p11: family, friends and functions.

Authors:  Ursula Rescher; Volker Gerke
Journal:  Pflugers Arch       Date:  2007-07-19       Impact factor: 3.657

10.  Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1.

Authors:  John F Reichard; Gregory T Motz; Alvaro Puga
Journal:  Nucleic Acids Res       Date:  2007-10-16       Impact factor: 16.971

View more
  7 in total

Review 1.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

2.  Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine.

Authors:  R Pattarini; Y Rong; K R Shepherd; Y Jiao; C Qu; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2012-04-24       Impact factor: 3.590

3.  Neuroprotective changes of striatal degeneration-related gene expression by acupuncture in an MPTP mouse model of Parkinsonism: microarray analysis.

Authors:  Yeong-Gon Choi; Sujung Yeo; Yeon-Mi Hong; Sabina Lim
Journal:  Cell Mol Neurobiol       Date:  2010-11-25       Impact factor: 5.046

4.  Gene dysregulation is restored in the Parkinson's disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm).

Authors:  Lesley Cheng; Camelia Y J Quek; Lin W Hung; Robyn A Sharples; Nicki A Sherratt; Kevin J Barnham; Andrew F Hill
Journal:  Sci Rep       Date:  2016-03-01       Impact factor: 4.379

5.  Validity of the MPTP-Treated Mouse as a Model for Parkinson's Disease.

Authors:  Cornelius J H M Klemann; Gerard J M Martens; Geert Poelmans; Jasper E Visser
Journal:  Mol Neurobiol       Date:  2015-02-13       Impact factor: 5.590

6.  The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor.

Authors:  Matthew L Neal; Alexa M Boyle; Kevin M Budge; Fayez F Safadi; Jason R Richardson
Journal:  J Neuroinflammation       Date:  2018-03-08       Impact factor: 8.322

7.  Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP(+).

Authors:  A K Krug; S Gutbier; L Zhao; D Pöltl; C Kullmann; V Ivanova; S Förster; S Jagtap; J Meiser; G Leparc; S Schildknecht; M Adam; K Hiller; H Farhan; T Brunner; T Hartung; A Sachinidis; M Leist
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.